Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial
Trial design: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verru...
Wedi'i Gadw mewn:
Prif Awduron: | , , , , , , , , , , , , , , , , , , |
---|---|
Fformat: | Llyfr |
Cyhoeddwyd: |
Elsevier,
2021-09-01T00:00:00Z.
|
Pynciau: | |
Mynediad Ar-lein: | Connect to this object online. |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
Rhif Galw: |
A1234.567 |
---|---|
Copi 1 | Ar gael |